ISPOR 22nd Annual International Meeting
Boston, MA, USA
May, 2017
Neurological Disorders-all
Cost Studies (CS)
Cost-Utility Analysis (CU)
Martin A
Crystallise Ltd., East Tilbury, UK
OBJECTIVES: To create an evidence map of studies reporting cost-utility models for multiple sclerosis, and the geographical jurisdictions for which these studies were conducted.

METHODS: We searched the database ( for cost-utility modellling studies in multiple sclerosis (MS) that were published between 1960 and 28th December 2016. We analysed the abstracts identified by the search to determine the different types of interventions modelled across the range of geographical locations, by date and type of MS. We presented the findings as an evidence map. RESULTS: We found a total of 42 abstracts. Of these, 14 were on relapsing-remitting MS, six were on progressive MS and 22 were on any type of MS or did not specify. Fifteen abstracts modelled the use of interferon beta-1b, 11 interferon beta-1a and seven were on any type of interferon-beta. Fourteen abstracts modelled the cost-utility of glatiramer acetate, four natalizumab and three each fingolimod, mitoxantrone and cannabinoids. Fourteen abstracts were set in the United Kingdom, 10 in the United States, four in Sweden, three in Spain, two in Germany and seven were international literature reviews or set in multiple countries. Twenty-one of the models used a societal perspective and nine a healthcare payer perspective, with 10 abstracts not specifying this. Of the 42 abstracts, 23 were published between 2010 and 2016 and none were published before 1997.

CONCLUSIONS: The majority of cost-utility models published for treatments of multiple sclerosis assessed interferon beta formulations or compared these treatments against newer products, and were generally relevant to the UK or US jurisdiction. The substantial impact of the disease on social and occupational functioning was reflected in the high proportion of models that were conducted from a societal perspective.